GemPharmatech Co., Ltd. (SHA:688046)
31.39
-3.11 (-9.01%)
Nov 16, 2026, 4:00 PM EST
GemPharmatech Revenue
GemPharmatech had revenue of 264.44M CNY in the quarter ending September 30, 2026, with 31.71% growth. This brings the company's total for the last twelve months to 941.80M, up 25.12% year-over-year. In the year 2025, GemPharmatech had annual revenue of 793.39M with 15.51% growth. That makes GemPharmatech the 20,104th largest company in the world by revenue and 3,693rd in China.
Revenue (ttm)
941.80M
Revenue Growth
+25.12%
P/S Ratio
13.64
Revenue / Employee
592.33K
Employees
1,692
Market Cap
12.84B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full GemPharmatech breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 793.39M | 106.55M | 15.51% |
| Dec 31, 2024 | 686.84M | 64.65M | 10.39% |
| Dec 31, 2023 | 622.19M | 105.64M | 20.45% |
| Dec 31, 2022 | 516.55M | 122.76M | 31.17% |
| Dec 31, 2021 | 393.79M | 131.87M | 50.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Anke Biotechnology (Group) | 2.34B |
| Tibet Cheezheng Tibetan Medicine | 2.23B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Jinyu Bio-technology | 1.60B |
| Nanjing Vazyme Biotech | 1.56B |
| BrightGene Bio-Medical Technology | 1.34B |
| Sinocelltech Group | 1.14B |
| Acrobiosystems | 1.03B |